The Experts below are selected from a list of 115638 Experts worldwide ranked by ideXlab platform
Enrique Dominguezmunoz - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication therapy vs antisecretory non eradication therapy with or without long Term Maintenance antisecretory therapy for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique DominguezmunozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
Javier P Gisbert - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication therapy vs antisecretory non eradication therapy with or without long Term Maintenance antisecretory therapy for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique DominguezmunozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
-
The Cochrane Library - Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique Dominguez-muñozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
Robert J Boland - One of the best experts on this subject based on the ideXlab platform.
-
implications of failing to achieve successful long Term Maintenance treatment of recurrent unipolar major depression
Biological Psychiatry, 1998Co-Authors: Martin B Keller, Robert J BolandAbstract:Abstract This is a review article that describes current data, issues, and controversies regarding long-Term Maintenance treatment of depression. The authors suggest that the issues represent a public health crisis. This paper will identify the need, from both a health-care and economic perspective, for more research on the efficacy of Maintenance treatment for this pernicious and lifelong disorder. Data will be reviewed on the natural course of unipolar depression, focusing on clinical predictors that increase the risk of a relapse or recurrence. This review will include new data from the National Institute of Mental Health Collaborative Depression Study. Failing to achieve adequate Maintenance treatment for unipolar recurrent major depression has psychopathological and psychosocial consequences, decreasing work productivity and the quality of a person's life. Published double-blind placebo-controlled studies on continuation treatment of major depression will be reviewed. The two competed double-blind placebo-controlled long-Term Maintenance studies of recurrent unipolar major depression will be discussed in detail. Despite the positive findings from research done to date, there remain many unresolved questions relating to the Maintenance treatment of recurrent unipolar major depression, and the need for research in this area is critical. The paper concludes with recommendations for long-Term Maintenance treatment of unipolar major depression.
Xavier Calvet - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication therapy vs antisecretory non eradication therapy with or without long Term Maintenance antisecretory therapy for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique DominguezmunozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
-
The Cochrane Library - Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique Dominguez-muñozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
Sam Khorrami - One of the best experts on this subject based on the ideXlab platform.
-
helicobacter pylori eradication therapy vs antisecretory non eradication therapy with or without long Term Maintenance antisecretory therapy for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique DominguezmunozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
-
The Cochrane Library - Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer
Cochrane Database of Systematic Reviews, 2004Co-Authors: Javier P Gisbert, Sam Khorrami, Fernando Carballo, Xavier Calvet, Emili Gene, Enrique Dominguez-muñozAbstract:Background Peptic ulcer is the main cause for upper gastrointestinal haemorrhage, and Helicobacter pylori (H.pylori) infection is the main etiologic factor for peptic ulcer disease. Maintenance antisecretory therapy is the standard long-Term treatment for patients with bleeding ulcers to prevent recurrent bleeding. The efficacy of H. pylori eradication for the prevention of rebleeding from peptic ulcer is unknown. Objectives To compare the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Search methods We searched the Cochrane Controlled Trials Register (the Cochrane Library issue 4, 2003), MEDLINE (January 1966 to January 2004), EMBASE (January 1988 to January 2004), CINAHL (January 1982 to January 2004), and reference lists of articles. We also conducted a manual search from several congresses. The search strategy was re-run in January 2005 and October 2008, but no new trials were found. Selection criteria Controlled clinical trials comparing the efficacy of H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Data collection and analysis Data extraction and quality assessment of studies was done by two reviewers. Study authors were contacted for additional information. Main results Seven studies with a total of 578 patients were included in the first comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 2.9%, and in the non-eradication therapy group without subsequent long-Term Maintenance antisecretory therapy it was 20% (OR 0.17, 95% CI 0.10 to 0.32; there was no statistical evidence of heterogeneity; NNT was 7, 95% CI 5 to 11). Three studies with a total of 470 patients were included in the second comparison: mean percentage of rebleeding in H. pylori eradication therapy group was 1.6%, and in non-eradication therapy group with long-Term Maintenance antisecretory therapy it was 5.6% (OR 0.24, 95% CI 0.09 to 0.67; heterogeneity was not demonstrated; NNT was 20, 95% CI 12 to 100). Subgroup analyses were carried out to examine the effect of NSAIDS and of excluding H.pylori eradication failures from the analyses. Authors' conclusions Treatment of H. pylori infection is more effective than antisecretory non-eradication therapy (with or without long-Term Maintenance antisecretory therapy) in preventing recurrent bleeding from peptic ulcer. All patients with peptic ulcer bleeding should be tested for H. pylori infection, and eradication therapy should be prescribed to H. pylori-positive patients.
